# SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
Canonical URL: https://biopharmsignal.com/news/SLS/sellas-life-sciences-provides-update-on-pivotal-phase-3-regal-trial-of-galinpepimut-s-gps-in-acute-myeloid-leukemia-aml
Ticker: SLS
Company: SELLAS Life Sciences Group, Inc.
Source: SELLAS Life Sciences Group, Inc.
Published: 2025-12-29 13:35 EST
Original Source URL: https://ir.sellaslifesciences.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-05-14 12:00 EST — [SELLAS Life Sciences to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/SLS/sellas-life-sciences-to-participate-in-upcoming-investor-conferences) — Source: SELLAS Life Sciences Group, Inc.
- 2026-05-12 20:05 EST — [SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SLS/sellas-life-sciences-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: SELLAS Life Sciences Group, Inc.
- 2026-03-19 20:05 EST — [SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SLS/sellas-life-sciences-reports-full-year-2025-financial-results-and-provides-corporate-update) — Source: SELLAS Life Sciences Group, Inc.
- 2026-03-17 20:30 EST — [SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference](https://biopharmsignal.com/news/SLS/sellas-life-sciences-to-present-preclinical-data-highlighting-potent-activity-of-sls009-in-aml-at-the-2026-aacr-conference) — Source: SELLAS Life Sciences Group, Inc.
- 2026-03-12 12:35 EST — [SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009](https://biopharmsignal.com/news/SLS/sellas-life-sciences-announces-enrollment-of-first-patient-in-newly-diagnosed-first-line-aml-trial-of-sls009) — Source: SELLAS Life Sciences Group, Inc.
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)